Consequently, more patients need to be identified to determine whether gray matter degeneration with either tubulopathy or cardiomyopathy are hallmarks of defects in NARS2 and PARS2, respectively, or just examples of a wider clinical spectrum. This evidence concerns the gene NARS2 and cardiomyopathy.